mtm adds €7m to series C
This article was originally published in Clinica
German cervical cancer diagnostics specialist mtm laboratories has raised a further €7m ($10.3m) in series C financing, bringing the total raised in the round to €39m. This latest tranche was led by new investor, Gilde Healthcare Partners (Utrecht, the Netherlands). As part of the financing, Arthur Franken, a partner at Gilde, will join mtm's supervisory board. Heidelberg-based mtm said the new capital will allow the company to advance clinical development and commercialisation of its p16INK4a-based CINtec and Cervatec tests. The products are designed to detect over-expression of p16INK4a, a biomarker for pre-cancerous and cancerous cells of the cervix.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.